Clinical Trials on Metastatic Prostate Adenocarcinoma

Total 23188 results

Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
German Oncology Center, Cyprus

Active, not recruiting

Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer (Hypo-Combi)

Prostate Adenocarcinoma | Radiation Toxicity

Cyprus
University of Miami

Completed

A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients (HIDRATEPRO)

Prostate Cancer | Prostate Adenocarcinoma | Radiation Toxicity

United States
Eli Lilly and Company

Completed

Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer

Adenocarcinoma of the Prostate

United States
Dana-Farber Cancer Institute

Completed

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Mary-Ellen Taplin, MD
Sanofi; Beth Israel Deaconess Medical Center; Genentech, Inc.; Duke University

Completed

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

Prostate Cancer | Adenocarcinoma of the Prostate

United States
AstraZeneca

No longer available

Casodex 150-mg Compassionate Use Trial for Subjects With Prostate Cancer

Adenocarcinoma of the Prostate
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Millennium: The Takeda Oncology Company

Completed

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

Evaluation of the Metastasis and Recurrence of Prostate Cancer

Prostate Cancer Recurrent | Prostate Cancer Metastatic | Prostate Cancer (Diagnosis) | Prostate Cancer Stage

China
National Cancer Institute (NCI)

Recruiting

Collection of Blood From Patients With Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Metastatic Prostate Cancer | Cancer Of Prostate | Prostate

United States
NanOlogy, LLC
US Biotest, Inc.

Completed

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

Adenocarcinoma of the Prostate

United States
Medical University of South Carolina
National Cancer Institute (NCI)

Completed

Docetaxel and Lycopene in Metastatic Prostate Cancer

Adenocarcinoma of the Prostate

United States
OHSU Knight Cancer Institute
Pfizer

Terminated

Pre-Prostatectomy Celecoxib or Placebo

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer

Prostate Cancer | Adenocarcinoma of the Prostate

United States
University of Washington
National Cancer Institute (NCI)

Completed

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer | PSA Progression | Castration Levels of Testosterone | Prostate Carcinoma Metastatic in the Bone

United States
Universität des Saarlandes

Recruiting

Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)

Prostate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic Cancer

Germany
Tampere University Hospital
University of Turku; University of Helsinki; Tampere University; Aalto University

Recruiting

Measuring Oncological Value of Exercise and Statin (MOVES)

Kidney Cancer | Breast Cancer | Metastatic Renal Cell Carcinoma | Ovarian Cancer | Prostate Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Ovarian Cancer | Metastatic Renal Cancer | Metastatic Kidney Cancer | Metastatic Ovary Cancer

Finland
Ignacio Puche Sanz
Chinese University of Hong Kong; UMC Utrecht; University of Padova; Medical University... and other collaborators

Not yet recruiting

BAseLine TEstosterone as a Prognostic and/or Predictive bioMARKer in mHSPC

Prostate Cancer Metastatic

Spain
Bayer
Orion Corporation, Orion Pharma

Completed

Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer (ARAMIS)

Prostate Cancer Non-Metastatic | Castration-Resistant

Belgium, France, Poland, Spain, Canada, United States, Estonia, Portugal, Taiwan, Japan, Russian Federation, Finland, Germany, Austria, Czechia, Hungary, Australia, Brazil, South Africa, Latvia, Italy, United Kingdom, Turkey, Serbia, Ro... and more
Bayer

Completed

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). (PHENIX)

Metastatic Castration-resistant Prostate Cancer (mCRPC)

United States
Jonsson Comprehensive Cancer Center
Novartis

No longer available

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Progressive Metastatic Castrate Resistant Prostate Cancer
National Cancer Institute (NCI)

Completed

Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Brown University
AstraZeneca; The Miriam Hospital; Rhode Island Hospital

Terminated

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes (337)

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Hormone-refractory Prostate Cancer

United States
Sun Yat-sen University

Not yet recruiting

The Effect of Metformin in Patients With Newly Diagnosed mHSPC

Metastatic Prostate Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Korea, Republic of, United States, Spain, France, Belgium, China, Taiwan, United Kingdom, Australia, Czechia, Hungary, Poland, Russian Federation
Medical University of Vienna

Recruiting

Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer

Locally Advanced and Metastatic Prostate Cancer

Austria
Athenex, Inc.

Completed

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

Bone-Metastatic, Castration-Resistant Prostate Cancer

United States
University of Texas Southwestern Medical Center

Completed

Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)

mCRPC | Metastatic Castrate-resistant Prostate Cancer

United States
Constellation Pharmaceuticals

Active, not recruiting

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Duke University

Completed

EXTEND Exercise Trial

Non-metastatic, Hormone naïve Prostate Cancer

United States
GenesisCare USA
Dendreon

Completed

A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T

Castrate Refractory Metastatic Prostate Cancer (mCRPC)

United States
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Determine Effect of Enzalutamide (MDV3100) on the Androgen Signaling Pathway in Correlation With the Anti-tumor Effects of Enzalutamide

Metastatic Progressive Castration-resistant Prostate Cancer

United States
Duke University
Bayer

Completed

Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer

Bone Metastatic Castration-Resistant Prostate Cancer

United States
Avionco LLC

Completed

Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Russian Federation
UNC Lineberger Comprehensive Cancer Center

Withdrawn

Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program (PETRUS)

Metastatic Castration Resistant Prostate Cancer Patients

France
National Cancer Institute (NCI)

Completed

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Jonsson Comprehensive Cancer Center

Withdrawn

Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer

Recurrent Prostate Cancer | Stage I Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

Clinical Trials on Metastatic Prostate Adenocarcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations